On October 12, 2023, DMK Pharmaceuticals Corporation filed a definitive proxy statement soliciting proxies and urged the shareholders to vote against shareholder proposals: (1) requesting that the Board approve any necessary amendments to the Company?s governing documents and policies to prohibit voting agreements connected to the issuance of new shares, except if the issuance is structured solely to obtain a quorum, (2) requesting that the Board approve any necessary amendments to the Company?s governing documents and policies so that only one vote per share issued is permitted, except if the issuance is structured solely to obtain a quorum, (3) requesting that the Company to amend the Bylaws so that stockholder approval is required to establish or materially amend management incentive plans, (4) requesting that the Company to amend the Bylaws so that directors in uncontested elections who fail to obtain a majority of the votes in favor of their election be removed from the Board, and (5) requesting that the Company to amend the Bylaws so that the Company?s stockholder notice provisions mirror federal annual meeting notice provisions, submitted by Jerald Hammann at the Company?s annual shareholders meeting scheduled to be held on November 9, 2023.